Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Cigarette smoking

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44346   clinical trials with a EudraCT protocol, of which   7374   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    212 result(s) found for: Cigarette smoking. Displaying page 5 of 11.
    « Previous 1  2  3  4  5  6  7  8  9  Next» Last»»
    EudraCT Number: 2009-015901-38 Sponsor Protocol Number: M/40464/26 Start Date*: 2010-02-02
    Sponsor Name:ALMIRALL, S.A.
    Full Title: Efficacy, safety and tolerability of two Fixed-Dose Combinations of Aclidinium bromide with two doses of Formoterol fumarate compared with Aclidinium bromide, Formoterol fumarate and placebo all ad...
    Medical condition: Moderate to severe chronic obstructive pulmonary disease (COPD)
    Disease: Version SOC Term Classification Code Term Level
    12.0 10009033 Chronic obstructive pulmonary disease LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) HU (Completed) CZ (Completed) RO (Completed)
    Trial results: View results
    EudraCT Number: 2006-004033-15 Sponsor Protocol Number: B2C108562 Start Date*: 2006-09-29
    Sponsor Name:GlaxoSmithKline Research and Development Limited
    Full Title: A multicentre, randomised, placebo-controlled, double-blind, 4-arm parallel-group, 2-week study to evaluate the safety, tolerability, pharmacodynamics and pharmacokinetics of GW642444H (100 and 400...
    Medical condition: Chronic Obstructive Pulmonary Disease
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed)
    Trial results: View results
    EudraCT Number: 2011-002665-38 Sponsor Protocol Number: M/34273/40 Start Date*: 2011-10-05
    Sponsor Name:Almirall S.A.
    Full Title: A MULTIPLE DOSE, RANDOMISED, DOUBLE-BLIND, PLACEBO CONTROLLED, 2 PERIOD CROSSOVER CLINICAL TRIAL TO ASSESS THE EFFECT OF ACLIDINIUM BROMIDE 400 μg BID ON EXERCISE ENDURANCE IN PATIENTS WITH STABLE ...
    Medical condition: Chronic obstructive pulmonary disease (COPD)
    Disease: Version SOC Term Classification Code Term Level
    14.0 10038738 - Respiratory, thoracic and mediastinal disorders 10010952 COPD LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) GB (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2005-005804-17 Sponsor Protocol Number: M/34273/24 Start Date*: 2007-02-08
    Sponsor Name:Laboratorios Almirall, S.A.
    Full Title: A Single Dose, Double-Blind, Double-Dummy, 3 Period Cross-Over, Placebo Controlled Clinical Trial To Assess the Rate of Onset of Action of Inhaled LAS 34273 200µg Compared To Placebo and Tiotropium...
    Medical condition: Phase III placebo controlled crossover trial to better characterise the acute effect of LAS 34273 on bronchodilation action in severe COPD patients.
    Disease: Version SOC Term Classification Code Term Level
    8.1 10009033 Chronic obstructive pulmonary disease LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed) DE (Completed) GB (Completed)
    Trial results: View results
    EudraCT Number: 2012-002156-16 Sponsor Protocol Number: DB2114951 Start Date*: 2014-08-13
    Sponsor Name:GlaxoSmithKline Research & Development Limited
    Full Title: A randomized, multi-center, double-blind, doubledummy, parallel group study to evaluate the efficacy and safety of umeclidinium/vilanterol compared with fluticasone propionate/salmeterol over 12...
    Medical condition: Chronic Obstructive Pulmonary Disease (COPD)
    Disease: Version SOC Term Classification Code Term Level
    17.0 100000004855 10010952 COPD LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: RO (Completed)
    Trial results: View results
    EudraCT Number: 2012-000525-45 Sponsor Protocol Number: DB2114930 Start Date*: 2013-01-10
    Sponsor Name:GlaxoSmithKline Research & Development Limited
    Full Title: DB2114930: A randomized, multi-center, double-blind, doubledummy, parallel group study to evaluate the efficacy and safety of umeclidinium/vilanterol compared with fluticasone propionate/salmetero...
    Medical condition: Chronic Obstructive Pulmonary Disease (COPD)
    Disease: Version SOC Term Classification Code Term Level
    14.1 100000004855 10010952 COPD LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GR (Completed)
    Trial results: View results
    EudraCT Number: 2015-001409-15 Sponsor Protocol Number: 201012 Start Date*: 2016-01-07
    Sponsor Name:GlaxoSmithKlineResearch & Developemnt Ltd
    Full Title: Study 201012: A Dose-Finding Study of batefenterol (GSK961081) via Dry Powder Inhaler in Patients with COPD.
    Medical condition: Subjects with COPD.
    Disease: Version SOC Term Classification Code Term Level
    18.1 100000004855 10010952 COPD LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2008-001889-81 Sponsor Protocol Number: IMD-10412003-1 Start Date*: 2008-06-24
    Sponsor Name:Institute of Medicinal Molecular Design, Inc.
    Full Title: A Phase IIa, Proof of Concept Study to Evaluate the Reduction in Inflammatory Biomarkers and Assess Airway Function Following Administration of IMD-1041 in Patients with Chronic Obstructive Pulmona...
    Medical condition: Chronic Obstructive Pulmonary Disease (COPD)
    Disease: Version SOC Term Classification Code Term Level
    9.1 10010952 COPD LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2020-002069-32 Sponsor Protocol Number: RPL554-CO-302 Start Date*: 2020-11-25
    Sponsor Name:Verona Pharma PLC
    Full Title: A Phase III Randomized, Double-Blind, Placebo- Controlled Study to Evaluate the Efficacy and Safety of Ensifentrine over 24 Weeks in Patients with Moderate to Severe Chronic Obstructive Pulmonary D...
    Medical condition: Chronic Obstructive Pulmonary Disease (COPD)
    Disease: Version SOC Term Classification Code Term Level
    21.1 10038738 - Respiratory, thoracic and mediastinal disorders 10009033 Chronic obstructive pulmonary disease PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SK (Completed) BE (Completed) DK (Completed) HU (Completed) BG (Completed)
    Trial results: View results
    EudraCT Number: 2018-001722-25 Sponsor Protocol Number: D6640C00006 Start Date*: 2018-09-04
    Sponsor Name:AstraZeneca AB
    Full Title: A Phase IIa, Randomised, Multi-centre, Double-blind, Placebo and Active-controlled, 3 Periods, Crossover Study to Investigate the Efficacy, Pharmacokinetics, Safety and Tolerability of Inhaled AZD8...
    Medical condition: Chronic Obstructive Pulmonary Disease (COPD)
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004855 10010952 COPD LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) DE (Completed)
    Trial results: View results
    EudraCT Number: 2011-005914-12 Sponsor Protocol Number: DB2116133 Start Date*: 2012-08-08
    Sponsor Name:GlaxoSmithKline Research & Development Limited
    Full Title: A Randomized, Double-Blind, 3-Way, Cross-Over Study to Evaluate Lung Function Response after Treatment with Umeclidinium 62.5mcg, Vilanterol 25mcg, and Umeclidinium/Vilanterol 62.5/25mcg Once-Daily...
    Medical condition: Chronic Obstructive Pulmonary Disease (COPD)
    Disease: Version SOC Term Classification Code Term Level
    15.0 10038738 - Respiratory, thoracic and mediastinal disorders 10010952 COPD LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) EE (Completed)
    Trial results: View results
    EudraCT Number: 2010-023091-10 Sponsor Protocol Number: HZC113108 Start Date*: 2011-04-05
    Sponsor Name:GlaxoSmithKline Research & Development Ltd
    Full Title: A 24-week study to evaluate the effect of fluticasone furoate/ vilanterol 100/25 mcg Inhalation Powder delivered once-daily via a Novel Dry Powder Inhaler on arterial stiffness compared with placeb...
    Medical condition: Chronic Obstructive Pulmonary Disease (COPD).
    Disease: Version SOC Term Classification Code Term Level
    16.1 100000004855 10010952 COPD LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) NO (Completed)
    Trial results: View results
    EudraCT Number: 2017-001074-42 Sponsor Protocol Number: 200879 Start Date*: 2017-12-01
    Sponsor Name:GlaxoSmithKline Research and Development Ltd.
    Full Title: A Phase IIb, Randomized (Stratified), Double-Blind (Sponsor Open), Parallel-Group, Placebo-Controlled, Dose-Finding Study of Nemiralisib (GSK2269557) Added to Standard of Care (SoC) Versus SoC Alon...
    Medical condition: Chronic Obstructive Pulmonary Disease
    Disease: Version SOC Term Classification Code Term Level
    20.0 10038738 - Respiratory, thoracic and mediastinal disorders 10009033 Chronic obstructive pulmonary disease PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Prematurely Ended) SE (Prematurely Ended) GB (Prematurely Ended) PL (Prematurely Ended) DE (Prematurely Ended) ES (Prematurely Ended) IT (Prematurely Ended) RO (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2010-021638-72 Sponsor Protocol Number: HZC113782 Start Date*: 2011-06-09
    Sponsor Name:GlaxoSmithKline Research & Development Ltd
    Full Title: HZC113782: A Clinical Outcomes Study to compare the effect of Fluticasone Furoate/Vilanterol Inhalation Powder 100/25mcg with placebo on Survival in Subjects with moderate Chronic Obstructive Pulmo...
    Medical condition: Subjects with moderate Chronic Obstructive Pulmonary Disease (COPD)
    Disease: Version SOC Term Classification Code Term Level
    18.0 10038738 - Respiratory, thoracic and mediastinal disorders 10009033 Chronic obstructive pulmonary disease PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Completed) SK (Completed) LV (Completed) AT (Completed) DE (Completed) GB (Completed) DK (Prematurely Ended) PL (Completed) GR (Completed) BG (Completed) ES (Completed) IT (Completed) NL (Completed) BE (Completed)
    Trial results: View results
    EudraCT Number: 2009-011600-27 Sponsor Protocol Number: M/34273/34 Start Date*: 2009-08-10
    Sponsor Name:Laboratorios Almirall, S.A.
    Full Title: Efficacy and safety of aclidinium bromide at two dose levels vs placebo when administered to patients with moderate to severe chronic obstructive pulmonary disease (COPD)
    Medical condition: Moderate to severe chronic obstructive pulmonary disease (COPD)
    Disease: Version SOC Term Classification Code Term Level
    9.1 10009033 Chronic obstructive pulmonary disease LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Completed) GB (Prematurely Ended) FR (Completed) ES (Completed) DE (Completed) HU (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2020-002086-34 Sponsor Protocol Number: RPL554-CO-301 Start Date*: 2020-11-09
    Sponsor Name:Verona Pharma PLC
    Full Title: A Phase III randomized, placebo-controlled study to evaluate the efficacy and safety of ensifentrine over 24 weeks (with a 48-week safety subset) in patients with chronic obstructive pulmonary dise...
    Medical condition: Chronic Obstructive Pulmonary Disease (COPD)
    Disease: Version SOC Term Classification Code Term Level
    21.1 10038738 - Respiratory, thoracic and mediastinal disorders 10009033 Chronic obstructive pulmonary disease PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Completed) DE (Completed) SK (Completed) HU (Completed) BG (Completed) GR (Completed) RO (Ongoing)
    Trial results: View results
    EudraCT Number: 2017-004564-35 Sponsor Protocol Number: 205739 Start Date*: 2018-08-14
    Sponsor Name:GlaxoSmithKline Research and Development Ltd.
    Full Title: A Phase IIa Randomized, Placebo-Controlled, Double-Blind (Sponsor Open) Study to Investigate the Clinical Efficacy, Safety, and Tolerability of Nemiralisib (GSK2269557) in Symptomatic COPD Particip...
    Medical condition: Chronic Obstructive Pulmonary Disease (COPD)/chronic bronchitis and emphysema
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004855 10010953 COPD exacerbation LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: SE (Completed) NL (Prematurely Ended) ES (Prematurely Ended) PL (Completed)
    Trial results: View results
    EudraCT Number: 2012-003106-27 Sponsor Protocol Number: RLV116974 Start Date*: 2012-11-01
    Sponsor Name:GlaxoSmithKline Research & Development Limited
    Full Title: A 12-Week Study to Evaluate the 24-Hour Pulmonary Function Profile of Fluticasone Furoate /Vilanterol (FF/VI) Inhalation Powder 100/25mcg Once Daily Compared with Fluticasone Propionate/Salmeterol ...
    Medical condition: Chronic Obstructive Pulmonary Disease (COPD)
    Disease: Version SOC Term Classification Code Term Level
    15.0 10038738 - Respiratory, thoracic and mediastinal disorders 10010952 COPD LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2014-000529-19 Sponsor Protocol Number: 201211 Start Date*: 2014-05-22
    Sponsor Name:GlaxoSmithKline R&D
    Full Title: A 12 week, Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study to Evaluate the Efficacy of Umeclidinium/Vilanterol 62.5/25mcg in Subjects with COPD
    Medical condition: Subjects with COPD
    Disease: Version SOC Term Classification Code Term Level
    16.1 100000004855 10010952 COPD LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed) DE (Completed) RO (Completed) BG (Completed)
    Trial results: View results
    EudraCT Number: 2014-000611-14 Sponsor Protocol Number: 201314 Start Date*: 2014-06-27
    Sponsor Name:GlaxoSmithKline Research & Development Ltd
    Full Title: A randomized, parallel group study to evaluate the effect of Umeclidinium (UMEC) added to Inhaled corticosteroid/ long-acting beta-agonist combination therapy in subjects with Chronic Obstructive P...
    Medical condition: in subjects with Chronic Obstructive Pulmonary Disease COPD
    Disease: Version SOC Term Classification Code Term Level
    17.0 100000004855 10010952 COPD LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed) DE (Completed) GR (Completed) CZ (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    « Previous 1  2  3  4  5  6  7  8  9  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Mon Jun 30 00:14:56 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA